Anti-EGFR (phospho Y1068)抗体(ab5644)

发表研究结果有使用 ab5644?请让我们知道,以便我们可以引用本数据表中的参考文章。

ab5644 被引用在 9 文献中.

  • Raha D  et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res 74:3579-90 (2014). PubMed: 24812274
  • Greenfield E  et al. Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors. Elife 3:N/A (2014). PubMed: 25490934
  • Ather F  et al. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PLoS One 8:e56112 (2013). WB ; Human . PubMed: 23405260
  • Wilson TR  et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-9 (2012). Human . PubMed: 22763448
  • Deng M  et al. Effect and risk of AEE788, a dual tyrosine kinase inhibitor, on regeneration in a rat liver resection model. Eur Surg Res 44:82-95 (2010). WB ; Rat . PubMed: 20090347
  • Donovan MJ  et al. A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib. Eur J Cancer 45:1518-26 (2009). PubMed: 19272767
  • Franovic A  et al. Human cancers converge at the HIF-2alpha oncogenic axis. Proc Natl Acad Sci U S A 106:21306-11 (2009). WB ; Human . PubMed: 19955413
  • Rothenberg SM  et al. Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A 105:12480-4 (2008). WB ; Human . PubMed: 18711136
  • McDermott U  et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 104:19936-41 (2007). PubMed: 18077425

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"